8-K: Bausch Health Appoints Steven Lee as New Chief Accounting Officer

Bausch Health Companies Inc. announced the appointment of Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective July 14, 2025.

Summary

• Bausch Health Companies Inc. appointed Steven Lee, 55, as Senior Vice President, Controller and Chief Accounting Officer.
• His appointment is effective July 14, 2025.
• Mr. Lee will receive an annual base salary of $450,000.
• He is eligible for an annual cash bonus with a target of 50% of his base salary, prorated based on his start date.
• He will also receive a one-time sign-on cash bonus of $50,000.
• A one-time sign-on equity grant with an aggregate fair value of $175,000, delivered as restricted stock units, will be granted under the 2014 Omnibus Incentive Plan.
• If Mr. Lee voluntarily resigns within the first year, he must repay the after-tax amount of the sign-on bonus.
• If terminated without cause, he will receive an amount equal to his annual base salary, subject to compliance with post-termination obligations and release of claims.
• Mr. Lee previously held senior financial roles at BrandSafway and Mohawk Industries, including Vice President and Chief Financial Officer of divisions, and Vice President, Corporate Controller, and Chief Accounting Officer.

Sentiment

Score: 7

Explanation: The appointment of an experienced Chief Accounting Officer is a positive step for corporate governance and financial oversight, indicating stability and a focus on strengthening the finance function. There are no negative implications or significant risks disclosed related to this specific event.

Positives

• Appointment of an experienced financial professional, Steven Lee, with over two decades of experience in financial transformation, mergers and acquisitions, and operational execution.
• Mr. Lee's background includes significant leadership roles as CFO and Chief Accounting Officer at BrandSafway and Mohawk Industries.
• The company's CFO, JJ Charhon, expressed excitement about Mr. Lee joining the finance leadership team, expecting his experience to support Bausch Health's transformation journey toward continued innovation and profitable growth.

Risks

• Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described.
• Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those described in Bausch Health's most recent annual and quarterly reports and other SEC/CSA filings.

Future Outlook

The company aims to continue its transformation journey toward continued innovation and profitable growth, with the new Chief Accounting Officer overseeing financial reporting and corporate controllership.

Management Comments

• "We are excited to add Steven to our finance leadership team as our new Controller and Chief Accounting Officer."
• "His depth and breadth of experience will be a great addition to the finance function as we continue to support Bausch Health's transformation journey toward continued innovation and profitable growth."

Industry Context

The appointment of a new Chief Accounting Officer is a standard corporate governance event for a global pharmaceutical company like Bausch Health. It reflects the ongoing need for robust financial reporting and controls, especially for a company undergoing a "transformation journey." This move aligns with general industry practices of strengthening financial leadership to support strategic objectives.

Comparison to Industry Standards

• The appointment of a Senior Vice President, Controller, and Chief Accounting Officer with over two decades of experience, including prior roles as CFO and CAO at other significant companies like BrandSafway and Mohawk Industries, aligns with industry standards for executive-level financial appointments in large, diversified pharmaceutical companies.
• Compensation packages, including base salary, performance-based bonuses, and equity grants, are typical for such senior roles in the pharmaceutical sector, though specific comparisons would require detailed peer group analysis.
• The inclusion of a repayment clause for the sign-on bonus if the executive voluntarily resigns within the first year is a common practice to protect the company's investment in new hires.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of an experienced Chief Accounting Officer can enhance confidence in the company's financial reporting and internal controls, potentially contributing to long-term value.
• Employees: The addition of a new senior leader in the finance department may bring new perspectives and leadership to the team.

Next Steps

• Steven Lee will officially assume his role as Senior Vice President, Controller and Chief Accounting Officer on July 14, 2025.
• He will oversee the company's financial reporting and corporate controllership.
• The company will continue its transformation journey toward continued innovation and profitable growth.

Key Dates

Recommendation

Keywords

Bausch Health Companies Inc., BHC, Steven Lee, Chief Accounting Officer, Controller, Senior Vice President, SEC Filing, 8-K, Management Appointment, Financial Reporting, Corporate Governance, Pharmaceutical Company